Anika Therapeutics | ANIK - الربح الإجمالي على المبيعات





الربح الإجمالي على المبيعات تغيير تاريخ
Abbott USD 6.54B 625M 2025-12
Agenus USD 34.2M 4.61M 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 256.47M 228.7M 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Insmed USD 217.69M 106.25M 2025-12
Integra LifeSciences USD 217.1M 10.11M 2025-12
Intrexon USD -297K 167K 2024-06
J&J USD 16.6B 118M 2025-12
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
MacroGenics USD 31.11M 30.14M 2025-12
Merit Medical Systems USD 195.35M 8.94M 2025-12
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Smith & Nephew USD 2.09B 117M 2025-12
Stryker USD 4.49B 633M 2025-12
Surmodics USD -11.54M 3.99M 2024-09
Veracyte USD 101.97M 10.69M 2025-12
Xencor USD 21M 22.61M 2025-09
Zimmer Biomet Holdings USD 1.27B 8.1M 2025-12